Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ALBANY MOLECULAR RESEARCH INCv350669_ex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

___________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2013

ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware 001-35622 14-1742717

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

26 Corporate Circle Albany, NY 12212
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (518) 512-2000


 (Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below) :

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

   

 
 
 

 

Item 8.01   Other Events.

 

On July 22, 2013, Albany Molecular Research, Inc. (the “Company”) issued a press release regarding a recent re-inspection of its Burlington, MA facility by the U.S. Food and Drug Administration. The full text of the press release, which was posted on the Company’s internet website, is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Item 9.01   Financial Statements and Exhibits

 

        (d)   Exhibits  
     
  99.1 Press release dated July 22, 2013, issued by Albany Molecular Research, Inc.

  

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 23, 2013 ALBANY MOLECULAR RESEARCH, INC.
     
  By: /s/ Michael M. Nolan
    Name: Michael M. Nolan
    Title: Vice President, Chief Financial Officer and Treasurer